CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 12 enrolled
Drug / intervention
Hydrocortisone +1 moredrug
Likely dose
Hydrocortisone 1 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01954056
NCT01954056Phase 3Completed

Hydrocortisone Treatment of Cardiovascular Insufficiency in Term and Late Preterm Infants: A Randomized Controlled Trial

NICHD Neonatal Research Network·interventional·Posted Oct 1, 2013·Updated Jul 6, 2021

In Brief

A Phase 3 clinical trial evaluating Hydrocortisone and Placebo for Infant, Newborn, Diseases and Cardiovascular Insufficiency. Completed, enrolled 12 participants across 18 sites.

Detailed Summary

This trial will evaluate the effects of a 7-day course of hydrocortisone therapy on short-term morbidity, cardiovascular function, long-term neurodevelopment, and mortality in critically ill, term and late preterm infants diagnosed with cardiovascular insufficiency as defined by a need for inotrope therapy in the first 72 hours of age.

Study Details

Timeline

Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedOct 1, 2013
Enrollment StartJun 19, 2014
Primary CompletionMar 20, 2018
TodayJul 1, 2026
Enrollment to primary: 3.8 yearsPosted 12.8 years ago

Interventions

Hydrocortisonedrug

• 7 day course of hydrocortisone (hydrocortisone sodium succinate, plain; will not have benzyl alcohol) given through intravenous line or by intramuscular injection if no intravenous line). 1 mg/kg loading dose x 1; 0.5 mg/kg q 6 hours x 12 doses; 0.5 mg/kg q 12 hours x 4 doses; 0.5 mg/kg q day x 1 dose

Placebodrug

7 days of intravenous or intramuscular placebo (normal saline in equal volume) 1 mg/kg loading dose x 1; 0.5 mg/kg q 6 hours x 12 doses; 0.5 mg/kg q 12 hours x 4 doses; 0.5 mg/kg q day x 1 dose